Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AAPG
AAPG
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AAPG News
Ascentage Pharma Reports Significant Revenue Growth in 2025 Financial Results
5d ago
Newsfilter
Ascentage Pharma Reports FY 2025 Earnings Beat Expectations
5d ago
seekingalpha
Ascentage Pharma's APG-3288 IND Approved, Initiating Clinical Study
Feb 05 2026
Newsfilter
Ascentage Pharma's Dual-Engine Growth: Global Innovation Strategy for 2026
Jan 15 2026
Globenewswire
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Ascentage Pharma's APG-3288 Receives FDA IND Clearance for Clinical Study
Jan 07 2026
Globenewswire
Novo Nordisk Receives FDA Approval for Wegovy, Shares Surge 8.6%
Dec 23 2025
Benzinga
Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday
Dec 16 2025
Benzinga
Ascentage Pharma Reports Four-Year Efficacy Data for Olverembatinib
Dec 09 2025
Newsfilter
Ascentage Pharma's Olverembatinib Shows Significant Efficacy with 21.2 Months EFS
Dec 09 2025
Globenewswire
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Meeting
Dec 09 2025
Globenewswire
Ascentage Pharma Reports Strong Efficacy of Olverembatinib in CML Treatment
Dec 09 2025
Globenewswire
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Conference
Dec 09 2025
Newsfilter
Ascentage Pharma Reports Olverembatinib Efficacy Data with 76.7% CCyR in CML Patients
Dec 09 2025
Newsfilter
Ascentage Pharma's Lisaftoclax Shows 31.8% Efficacy in Myeloid Malignancies
Dec 08 2025
Newsfilter
Ascentage Pharma's Lisaftoclax Shows 31.8% Efficacy in Myeloid Malignancies
Dec 08 2025
Globenewswire
Show More News
